Compare · MNK vs PFE
MNK vs PFE
Side-by-side comparison of Mallinckrodt plc (MNK) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNK and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE carries a market cap of $153.59B.
- PFE has hit the wire 10 times in the past 4 weeks while MNK has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 0 for MNK).
- Company
- Mallinckrodt plc
- Pfizer Inc.
- Price
- $0.33-20.01%
- $26.98+1.20%
- Market cap
- -
- $153.59B
- 1M return
- -
- -1.21%
- 1Y return
- -
- +17.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 10
- Recent ratings
- 0
- 25
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest MNK
- Mallinckrodt Receives Court Approval For "First Day" Motions To Support Ongoing Operations
- Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations
- NYSE American To Begin Delisting Proceedings Against Mallinckrodt
- Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
- Hit By Opioid Lawsuits Mallinckrodt Files For Second Bankruptcy In Just Three Years
- On August 22, 2023, Mallinckrodt Received A Grand Jury Subpoena From The U.S. Attorney's Office For The Western District Of Virginia Seeking The Production Of Data And Information From July 17, 2017, To The Present - 8K
- Mallinckrodt Initiates Voluntary Prepackaged Chapter 11 Proceedings
- Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations
- Rite Aid Once Top Drugstore Chain Lost Over 80% Of Stock Value In One Year: Opioid Litigation Takes Toll
- 12 Health Care Stocks Moving In Friday's Intraday Session
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities